SG11202003318QA - Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy - Google Patents
Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapyInfo
- Publication number
- SG11202003318QA SG11202003318QA SG11202003318QA SG11202003318QA SG11202003318QA SG 11202003318Q A SG11202003318Q A SG 11202003318QA SG 11202003318Q A SG11202003318Q A SG 11202003318QA SG 11202003318Q A SG11202003318Q A SG 11202003318QA SG 11202003318Q A SG11202003318Q A SG 11202003318QA
- Authority
- SG
- Singapore
- Prior art keywords
- products
- methods
- reverse transcriptase
- nucleoside reverse
- transcriptase inhibitor
- Prior art date
Links
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000012544 monitoring process Methods 0.000 title 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762572126P | 2017-10-13 | 2017-10-13 | |
PCT/US2018/055961 WO2019075487A1 (en) | 2017-10-13 | 2018-10-15 | Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003318QA true SG11202003318QA (en) | 2020-05-28 |
Family
ID=66101731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003318QA SG11202003318QA (en) | 2017-10-13 | 2018-10-15 | Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy |
Country Status (9)
Country | Link |
---|---|
US (1) | US11795239B2 (en) |
EP (1) | EP3695225A4 (en) |
JP (1) | JP2020536588A (en) |
KR (1) | KR20200086678A (en) |
CN (1) | CN111727372A (en) |
AU (1) | AU2018347704A1 (en) |
CA (1) | CA3079140A1 (en) |
SG (1) | SG11202003318QA (en) |
WO (1) | WO2019075487A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3948278A1 (en) * | 2019-04-01 | 2022-02-09 | OraSure Technologies, Inc. | System and method for detecting therapeutic agents to monitor adherence to a treatment regimen |
US20220372171A1 (en) * | 2019-09-20 | 2022-11-24 | Abbott Rapid Diagnostics International Unlimited Company | Antibody directed against tenofovir and derivatives thereof |
US20220196641A1 (en) * | 2020-12-18 | 2022-06-23 | Orasure Technologies, Inc. | Reagents, methods, and systems for detecting therapeutic agents to monitor adherence to nucleoside reverse transcriptase inhibitor metabolites |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014364A1 (en) * | 2002-08-07 | 2004-02-19 | Idenix (Cayman) Limited | Substituted phenylindoles for the treatment of hiv |
US20110200609A1 (en) * | 2002-09-12 | 2011-08-18 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence |
ES2320252T3 (en) * | 2004-09-17 | 2009-05-20 | Idenix Pharmaceuticals, Inc. | PHOSFOINDOLS AS HIV INHIBITORS. |
WO2007103740A2 (en) * | 2006-03-01 | 2007-09-13 | Ark Diagnostics | Immunoassays, haptens, immunogens and antibodies for anti-hiv therapeutics |
CN103261222B (en) | 2010-09-10 | 2017-07-28 | 医疗免疫有限公司 | Antibody derivatives |
US20200200735A9 (en) * | 2016-02-22 | 2020-06-25 | Ursure, Inc. | System and method for detecting therapeutic agents to monitor adherence to a treatment regimen |
WO2019018747A1 (en) | 2017-07-20 | 2019-01-24 | Trustees Of Boston University | Tenofovir detection assay |
US20220196641A1 (en) * | 2020-12-18 | 2022-06-23 | Orasure Technologies, Inc. | Reagents, methods, and systems for detecting therapeutic agents to monitor adherence to nucleoside reverse transcriptase inhibitor metabolites |
-
2018
- 2018-10-15 WO PCT/US2018/055961 patent/WO2019075487A1/en unknown
- 2018-10-15 CA CA3079140A patent/CA3079140A1/en active Pending
- 2018-10-15 AU AU2018347704A patent/AU2018347704A1/en active Pending
- 2018-10-15 SG SG11202003318QA patent/SG11202003318QA/en unknown
- 2018-10-15 EP EP18865724.1A patent/EP3695225A4/en active Pending
- 2018-10-15 JP JP2020542052A patent/JP2020536588A/en active Pending
- 2018-10-15 KR KR1020207013636A patent/KR20200086678A/en not_active Application Discontinuation
- 2018-10-15 CN CN201880081029.3A patent/CN111727372A/en active Pending
- 2018-10-15 US US16/755,100 patent/US11795239B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3695225A1 (en) | 2020-08-19 |
CA3079140A1 (en) | 2019-04-18 |
CN111727372A (en) | 2020-09-29 |
WO2019075487A1 (en) | 2019-04-18 |
AU2018347704A1 (en) | 2020-05-28 |
US20200239598A1 (en) | 2020-07-30 |
EP3695225A4 (en) | 2021-06-30 |
KR20200086678A (en) | 2020-07-17 |
US11795239B2 (en) | 2023-10-24 |
JP2020536588A (en) | 2020-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269462A (en) | Mdm2 inhibitors and therapeutic methods using the same | |
HK1243901A1 (en) | Devices and methods for ablation of the skin | |
EP3160475C0 (en) | Substituted nucleosides and nucleotides to treat filoviridae infections | |
DK3122752T3 (en) | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | |
HUE059131T2 (en) | Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor | |
PT3286166T (en) | Inhibitors of human immunodeficiency virus replication | |
HK1225617A1 (en) | 4’-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication | |
EP3352781A4 (en) | 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof | |
HK1249497A1 (en) | Ebna1 inhibitors and methods using same | |
HK1254954A1 (en) | Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment | |
PL3125894T3 (en) | Prodrugs of hiv reverse transcriptase inhibitors | |
SG11202003318QA (en) | Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy | |
IL267238A (en) | Heparanase inhibitors and use thereof | |
ZA201705530B (en) | 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors | |
SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
HK1250028A1 (en) | 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors | |
GB201705413D0 (en) | Shale hydration inhibitor and method of use | |
GB2541039B (en) | Devices for and methods of diagnosis and/or monitoring dysphagia | |
PT3107913T (en) | Inhibitors of human immunodeficiency virus replication | |
PT3433257T (en) | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | |
IL267243A (en) | Heparanase inhibitors and use thereof | |
GB201404656D0 (en) | Real-time systems and methods for management of alimentation |